Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Clinical trial NCT03310957 · COMPLETED
Trial details
- NCT number
- NCT03310957
- Sponsor
- Seagen Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-27
- Primary completion
- 2024-09-30
- Enrollment
- 185
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.